SEC Form 4 · accession 0001209191-18-057370
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2018 | M | 1,796 | $91.05 | A | 40,909 | D | |
| Common Stock | Nov 2, 2018 | S | 1,796 | $175.36 | D | 39,113 | D | |
| Common Stock | Nov 5, 2018 | M | 2,330 | $86.52 | A | 41,443 | D | |
| Common Stock | Nov 5, 2018 | S | 2,330 | $172.08 | D | 39,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Nov 2, 2018 | M | 1,796 | A | — | Feb 1, 2026 | Common Stock | 1,796 | 8,980 | D |
| Stock Option (Right to Buy)F3 | $86.52 | Nov 5, 2018 | M | 2,330 | A | — | Feb 2, 2027 | Common Stock | 2,330 | 20,969 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 02/02/2016.
- F3The option vests in 16 quarterly installments from 02/03/2017.